S moking assessment and cessation counseling are recommended at all clinical encounters for all current smokers, 1 including those with rheumatoid arthritis (RA), 2 but occur variably. 3 In RA, tobacco use is strongly associated with increased RA incidence, 4 worse RA severity, and treatment failures. 5 Smoking also contributes to the leading causes of death in RA: cardiovascular, pulmonary, and oncologic diseases. 6 Systematic reviews show that smoking cessation counseling results in 1.7 times higher quit rates. 7 Consequently, RA experts and guidelines recommend smoking cessation counseling for current smokers. 2, 8 However, very little is known regarding the rate of rheumatologists performing tobacco counseling. Estimates from retrospective physician surveys indicate that only half of rheumatologists self-reported that they provided smoking cessation counseling to the majority of their patients. 9 Moreover, self-reporting may overestimate true counseling rates.
Given this uncertainty regarding rheumatologist smoking cessation practices, the objective of our study was to examine the frequency and predictors of smoking cessation counseling by rheumatologists in visits with active RA smokers with at least 1 additional cardiovascular disease (CVD) risk factor. Using the model of competing demands, which posits that preventive health counseling needs compete with the patient's active problems and demands, 10 we hypothesized that smoking cessation counseling would occur more frequently in visits in which RA was perceived to be controlled.
MATERIALS AND METHODS

Patients and Setting
This observational cohort study investigated RA visits in 3 rheumatology clinics within a large academic multispecialty medical group between 2004 and 2011. This secondary data analysis study combined 2 previously described cohorts of RA patients identified using a published algorithm defined as 2 or more visits with International Classification of Diseases, Ninth Edition claims for RA (714.0-714.33, 714.4, 714.80, 7.14.81, 714.89).
11 All patients were 20 years or older and seen regularly for primary and rheumatology care (≥2 health system visits with at least 1 primary care visit in 24 months) and had rheumatology clinic notes clearly documenting RA in the absence of another specific inflammatory arthritis diagnosis (Fig.) . One cohort included RA patients with prevalent hypertension 12 according to electronic health record (EHR) algorithms using the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 13 The second cohort included patients who were eligible for cholesterol screening or control.
14,15 A minority of patients were included in both cohorts; these duplicate visits were removed prior to analysis. Patients were excluded from analysis if blood pressure or cholesterol normalized or if they died prior to cohort entry. Current smokers were identified by the EHR smoking status documented during registration or vital sign collection. Using a standard form, trained abstractors reviewed all rheumatology RA clinic visit notes on eligible patients until death, migration, risk factor control, or January 1, 2012. A visit-level data set was then constructed to facilitate manual abstraction of visit notes during the eligible period.
Data Sources
Using a standard form, trained abstractors reviewed all rheumatology RA clinic visit notes on eligible patients. For every 200 charts reviewed by an individual abstractor, quality assurance audits were performed on 10 charts to ensure agreement between abstractors. The project was approved by the University of Wisconsin Health Sciences institutional review board under no. 2012-0053 with a waiver of informed consent.
Outcomes
Our primary outcome was the occurrence of smoking cessation counseling among current smokers identified using an abstraction template (see Abstraction Template Table, Supplemental Data File 1, http://links.lww.com/RHU/A72). Counseling encompassed any discussion of smoking or its risks, advice or instructions to quit or cut back, referral to primary care or a tobacco quit line, and the provision of cessation medications. The secondary outcome was the documentation of smoking status by the rheumatologist. Both outcomes were abstracted from visit notes.
Variables
Our primary explanatory variable was whether the patient's RA was controlled. Because RA disease activity measures were not available for all visits during the study period, we used perceived RA control at the visit according to the rheumatologist's note, which was categorized as "controlled" or "not controlled." Control was interpreted from rheumatologists' impressions describing that RA was: well controlled; under good control; in remission, inactive, or quiescent; or showing no active disease or arthritis. Lack of control was interpreted from impressions that RA was uncontrolled, active, mild, minimal, relatively controlled, or improving.
Additional explanatory variables included patient baseline sociodemographic factors and comorbidities. Sociodemographic factors included age, sex, race, marital status, language, and ever being enrolled in Medicaid. Baseline comorbidities included body mass index (BMI) categories (underweight, normal weight, overweight, obese), CVD, diabetes mellitus, hyperlipidemia, hypertension, pulmonary disease, and anxiety and/or depression (see Table  of International Classification of Diseases, Ninth Edition Code Reference Definitions, Supplemental Data File 2, http://links. lww.com/RHU/A73). Cardiovascular disease was defined to include congestive heart failure, peripheral vascular disease, transient ischemic attack/stroke, myocardial infarction, and ischemic heart disease. In order to control for baseline composite comorbidity burden and health needs, we used a validated single score calculated via the Johns Hopkins Adjusted Clinical Groups CaseMix System (version 10). Correlation matrices showed no evidence of collinearity for covariates in the full model.
Statistical Analysis
In order to compare differences in smokers and nonsmoking patients and visits with and without perceived RA control, we used χ 2 testing for categorical variables and analysis of variance for continuous variables. We performed unadjusted regression analysis for each explanatory variable with our primary outcome, followed by stepwise multivariable logistic regression analysis to examine predictors of smoking cessation counseling. For all statistical tests, we considered P < 0.05 significant. Patient sample selection and data variable creation were conducted using SAS version 9.1.3 (SAS Institute, Inc. Cary, NC); statistical analysis was conducted using Stata version 12 (StataCorp LP. College Station, TX).
RESULTS
A total of 612 RA patients (3396 visits) were identified, of whom 546 (89%) had tobacco status documented. Our analysis included 360 visits with 67 current smokers with RA (Table 1) . Smokers with RA had a mean age of 54 (SD, 11) years. Notably, 0% of smokers and 10% of nonsmokers were older than 80 years. Consistent with RA epidemiology, 61% of smokers with RA were women, and 81% were white. Compared with nonsmokers, current smokers were younger, less often female, less often white, and more likely to have ever received Medicaid; had lower BMI; and were more likely to have baseline CVD.
Examination of our secondary outcome revealed that rheumatologists documented smoking status in the clinic note in 39% of 360 visits with electronically documented smokers. Of the 360 visits, 31% of visits were classified as the patient having subjectively controlled RA (Table 1) , in contrast to nonsmokers in whom 39% of visits had subjectively controlled RA (data not shown). Among visits involving smokers without controlled RA, a higher proportion had ever received Medicaid, a marker of socioeconomic adversity. Visits with uncontrolled RA also included a higher percentage of patients with comorbid anxiety/depression and hypertension and a lower percentage of CVD, renal disease, and hyperlipidemia compared with visits with patients with controlled RA.
Smoking cessation counseling, our primary end point, was documented in 10% of visits. Overall, documentation of smoking cessation counseling was less likely to occur in clinic visits of smoking patients with subjectively controlled RA versus clinic visits of patients with uncontrolled RA (odds ratio [OR], 0.3; confidence interval [CI], 0.1-0.97; P = 0.02) ( Table 2 ). Obese patients were less likely to receive smoking cessation counseling (OR, 0.4; CI, 0.1-0.9; P = 0.03). Patients with comorbid cardiovascular (OR, 2.8; CI, 1.3-6.2; P = 0.009) or pulmonary disease (OR, 3.5; CI, 2.7-18.9; P < 0.001) were more likely to receive cessation counseling. In a multivariable model, RA control (OR, 0.3; CI, 0.1-0.97; P = 0.043), obesity (OR, 0.3; CI, 0.1-0.9; P = 0.04), and pulmonary disease (OR, 5.0; CI, 1.7-14.4; P = 0.003) continued to be significant predictors. Only 2 notes (of 360 total notes [0.56%]) documented quit line referral; no cessation medications were discussed and documented in any of the RA clinic notes.
DISCUSSION
Despite the deleterious effects of smoking on RA and cardiovascular health, we found low rates of rheumatologists acknowledging smoking status (39%) and offering cessation counseling (10%) to current smokers. These findings are consistent with prior studies reporting poor health behavioral counseling among generalists and specialists. Far from optimal, these findings might be explained by rheumatologists' perceived limited role in preventive care. In our prior qualitative interviews, some rheumatologists reported being less likely to identify or manage CVD risk factors (e.g., hypertension, smoking) because of the perception that this is the role of primary care physicians. 16 We hypothesized that patients with controlled RA would be more likely to receive smoking cessation counseling because of the model of competing demands. In this application of the model, the rheumatologist needs to spend less fixed clinic time managing the patient's RA, resulting in more available time for health behavior counseling. Surprisingly, in contrast to our hypothesis, we found that patients with controlled RA were less likely to receive smoking cessation counseling.
The results of our study may instead be explained by rheumatologists' assumptions and beliefs that the poor RA control is a result of tobacco use. Under this paradigm, rheumatologists would be less likely to address tobacco use unless it was perceived as directly influencing the RA. In the case of uncontrolled RA, rheumatologists might be more inclined to provide smoking cessation counseling if they reason that smoking is worsening RA severity. The rheumatologist would also provide more counseling when confronted with a patient with a smoking-related disease, as was seen in this study in patients with CVD and pulmonary disease.
Primary prevention, however, prior to the development of smoking-related complications, is a critical unmet public health need in RA. Recent reports indicate a 1.8 higher odds of incident COPD among RA patients compared with non-RA patients. 17 In addition, it is well established that patients with RA face 60% higher risk of premature CVD. 18 Given that smoking is among the most threatening yet modifiable risk factors for the leading causes of premature death in RA, rheumatology clinics have an important opportunity to impact population health by improving smoking cessation care. One significant barrier to smoking cessation is that RA patients are often unaware of the causative relationship between RA severity and smoking. 19 Making this connection more explicit could be critical to motivate cessation.
Instituting or collaborating with smoking cessation programs can improve cessation rates. One Spanish rheumatology clinic reported a 4-fold increase in quit rates after developing a smoking cessation protocol. 20 North American tobacco quit line referrals are widely available, free, and highly effective tools in supporting patients to quit smoking. 1 Yet, as shown by our low referral rate (≤1%), they are underutilized in RA clinics.
One successful way to overcome low preventive care delivery is staff protocol interventions. According to competing demands frameworks, this shifts demands from the physician to support staff and systematizes practice. 10 We are currently testing the feasibility of rheumatology staff protocols to facilitate EHR referrals to the quit line for interested patients (https://www.hipxchange. org/QuitConnect). Future work should examine this and other strategies to support smoking cessation in RA patients to reduce harms of RA and improve long-term patient outcomes.
We acknowledge several limitations of this study. Examining only 1 health system potentially limits generalizability; however, we did assess 3 separate clinics with 15 providers. The sample size of smokers with active RA was low (n = 57), which was a major limitation of our study; however, we were analyzing at the visit level, and there were 360 visits included in the analyses. Our secondary data analysis study included patients only if they had uncontrolled blood pressure or cholesterol, yet one might expect more counseling for patients with multiple cardiovascular risk factors. Our definition of disease control reflected the subjective impressions of the rheumatologist rather than objective disease activity scores, which were not available for all years. Nevertheless, in practice, decisions are commonly based on subjective impressions rather than calibrated data. In addition, we recognize that physicians may not consistently document counseling. Despite these limitations, these results clearly refute our hypothesis. However, this study should be repeated with larger numbers of RA patients who smoke not restricted to those with comorbid CVD risk factors.
In contrast to our hypothesis, perceived uncontrolled RA predicted more likely smoking cessation counseling by rheumatologists than controlled RA, but overall counseling rates were low at 10%. Counseling occurred more often for patients with cardiopulmonary complications. Our findings highlight the need for systematic, proactive smoking cessation counseling or referral processes in rheumatology clinics prior to smoking-related complications.
KEY POINTS
• Rheumatologists infrequently perform smoking cessation counseling with RA patients (10% of eligible visits).
• Counseling occurred more frequently in visits involving patients without RA control or with smoking-related complications.
• Systematic smoking cessation practices should be investigated to prevent smoking-related complications in RA patients.
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